« Return to News | Drug Sponsors

Recordati acquires Farma-Projekt in Poland

Friday, August 3, 2012 10:48 AM

Recordati, a European pharmaceutical group based in Milan, Italy, has agreed to acquire 100% of the share capital of Farma-Projekt, a Polish pharmaceutical company, for $21.5 million.

Farma-Projekt, which earned $14.2 million in sales last year, has operated on the Polish pharmaceutical market since 2003. The company employs 135 personnel and markets cardiovascular and urological treatments, as well as dietary supplements.

“The acquisition of Farma-Projekt is another step forward in our strategy to increase our business in the Central and Eastern European markets which are growing at interesting rates” said Giovanni Recordati, chairman and CEO of Recordati. “Poland has a large population and currently a strong demand for pharmaceuticals. The Polish pharmaceutical market is the second largest in Central and Eastern Europe and in the last five years has been growing at an average annual rate of 6.8%. In particular, the market for self-medication products has grown at an average rate of 11.2% per year.”

Recordati is already present in Poland with its subsidiary Recordati Polska which it established in 2011. The addition of Farma-Projekt will increase it’s presence in Poland.

The transaction is expected to close in the following months.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.